Patient and disease characteristics
| Characteristic . | Value (n = 10) . | % . |
|---|---|---|
| Age, median (range), y | 58 (36-71) | |
| Sex | ||
| Female | 3 | 30 |
| Male | 7 | 70 |
| Race | ||
| White | 3 | 30 |
| Black | 2 | 20 |
| Caucasian | 3 | 30 |
| Asian | 1 | 10 |
| Others | 1 | 10 |
| MM subtype | ||
| IgG | 7 | 70 |
| IgA | 1 | 10 |
| Light chain only | 2 | 20 |
| Light chain | ||
| Kappa | 6 | 60 |
| Lambda | 4 | 40 |
| HR FISH/CG | ||
| Yes | 4 | 40 |
| No | 4 | 40 |
| Unknown | 2 | 20 |
| t(4,14) | ||
| Yes | 1 | 10 |
| No | 7 | 70 |
| Unknown | 2 | 20 |
| t(4,16) | ||
| Yes | 0 | 0 |
| No | 8 | 80 |
| Unknown | 2 | 20 |
| del(17p) | ||
| Yes | 1 | 10 |
| No | 7 | 70 |
| Unknown | 2 | 20 |
| 1q21 gain/amp | ||
| Yes | 4 | 40 |
| No | 5 | 50 |
| Unknown | 1 | 10 |
| R-ISS | ||
| I | 1 | 10 |
| II | 4 | 40 |
| III | 0 | 0 |
| Unknown | 5 | 50 |
| ECOG | ||
| 0 | 1 | 10 |
| 1 | 6 | 60 |
| 2 | 3 | 30 |
| 3-4 | 0 | 0 |
| Extramedullary disease | ||
| CNS EMD | 10 | 100 |
| Non-CNS extraosseous EMD | 6 | 60 |
| Para-medullary EMD | 3 | 30 |
| Number of prior lines of therapy, median (range) | 6 (4-10) | |
| Prior ASCT | ||
| Yes | 9 | 90 |
| No | 1 | 10 |
| Triple-class refractory∗ | ||
| Yes | 8 | 80 |
| No | 2 | 20 |
| Penta-class refractory† | ||
| Yes | 7 | 70 |
| No | 3 | 30 |
| Prior BCMA-directed therapy | ||
| Yes | 3 | 30 |
| No | 7 | 70 |
| Characteristic . | Value (n = 10) . | % . |
|---|---|---|
| Age, median (range), y | 58 (36-71) | |
| Sex | ||
| Female | 3 | 30 |
| Male | 7 | 70 |
| Race | ||
| White | 3 | 30 |
| Black | 2 | 20 |
| Caucasian | 3 | 30 |
| Asian | 1 | 10 |
| Others | 1 | 10 |
| MM subtype | ||
| IgG | 7 | 70 |
| IgA | 1 | 10 |
| Light chain only | 2 | 20 |
| Light chain | ||
| Kappa | 6 | 60 |
| Lambda | 4 | 40 |
| HR FISH/CG | ||
| Yes | 4 | 40 |
| No | 4 | 40 |
| Unknown | 2 | 20 |
| t(4,14) | ||
| Yes | 1 | 10 |
| No | 7 | 70 |
| Unknown | 2 | 20 |
| t(4,16) | ||
| Yes | 0 | 0 |
| No | 8 | 80 |
| Unknown | 2 | 20 |
| del(17p) | ||
| Yes | 1 | 10 |
| No | 7 | 70 |
| Unknown | 2 | 20 |
| 1q21 gain/amp | ||
| Yes | 4 | 40 |
| No | 5 | 50 |
| Unknown | 1 | 10 |
| R-ISS | ||
| I | 1 | 10 |
| II | 4 | 40 |
| III | 0 | 0 |
| Unknown | 5 | 50 |
| ECOG | ||
| 0 | 1 | 10 |
| 1 | 6 | 60 |
| 2 | 3 | 30 |
| 3-4 | 0 | 0 |
| Extramedullary disease | ||
| CNS EMD | 10 | 100 |
| Non-CNS extraosseous EMD | 6 | 60 |
| Para-medullary EMD | 3 | 30 |
| Number of prior lines of therapy, median (range) | 6 (4-10) | |
| Prior ASCT | ||
| Yes | 9 | 90 |
| No | 1 | 10 |
| Triple-class refractory∗ | ||
| Yes | 8 | 80 |
| No | 2 | 20 |
| Penta-class refractory† | ||
| Yes | 7 | 70 |
| No | 3 | 30 |
| Prior BCMA-directed therapy | ||
| Yes | 3 | 30 |
| No | 7 | 70 |
Amp, amplification; ASCT, autologous stem cell transplantation; CG, Cytogenetics; ECOG, Eastern Cooperative Oncology Group performance status; FISH, fluorescence in situ hybridization; IgA, immunoglobulin A; IgG, immunoglobulin G; R-ISS, Revised Multiple Myeloma International Staging System.
Triple-class refractory was defined as MM refractory to an immunomodulatory (IMiD) drug, a proteosome inhibitor (PI), and an anti-CD38 antibody.
Penta-class refractory was defined as MM refractory to 2 IMiDs, 2 PIs, and an anti-CD38 antibody.